Abstract
Imbalances in gut microbiota are associated with metabolic disorder, which are a group of obesity-related metabolic abnormalities that increase an individual’s risk of developing type 2 diabetes (T2D) and Alzheimer’s disease (AD). Although a number of risk factors have been postulated that may trigger the development of AD, the root cause of this disease is still a matter of debate. This review further investigates the etiology of AD by accumulating the current role played by gut microbiota in human, and trying to establish an inter-link between T2D and AD pathogenesis. There is a growing body of evidence which suggests that obesity is associated with alteration in the normal gut flora, reduced bacterial diversity, metabolic pathways and altered representation of bacterial genes. Obesity and T2D are considered to be induced as a result of changes within the composition of gut microbiota. The evidence gathered so far clearly advocates the involvement of gut microbes in causing obesity, a state of chronic and low-grade inflammation. Hence, understanding the microbiota of the gut is significant in relation to inflammation, as it is a key contributor for diabetes which has a direct relation to the AD pathogenesis. Comparative analysis of gut microbiota may enable further novel insight into the complex biology of AD, which is very important in order to take preventive measure such as early diagnosis, identification of new therapeutic targets and development of novel drugs.
Keywords: Alzheimer's disease, Inflammation, Insulin resistance, Macrobiotic, obesity, Tall–like receptor, type-2 diabetes.
CNS & Neurological Disorders - Drug Targets
Title:A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimer’s Disease Pathogenicity: An Update
Volume: 13 Issue: 3
Author(s): Mohammad Z. Alam, Qamre Alam, Mohammad A. Kamal, Adel M. Abuzenadah and Absarul Haque
Affiliation:
Keywords: Alzheimer's disease, Inflammation, Insulin resistance, Macrobiotic, obesity, Tall–like receptor, type-2 diabetes.
Abstract: Imbalances in gut microbiota are associated with metabolic disorder, which are a group of obesity-related metabolic abnormalities that increase an individual’s risk of developing type 2 diabetes (T2D) and Alzheimer’s disease (AD). Although a number of risk factors have been postulated that may trigger the development of AD, the root cause of this disease is still a matter of debate. This review further investigates the etiology of AD by accumulating the current role played by gut microbiota in human, and trying to establish an inter-link between T2D and AD pathogenesis. There is a growing body of evidence which suggests that obesity is associated with alteration in the normal gut flora, reduced bacterial diversity, metabolic pathways and altered representation of bacterial genes. Obesity and T2D are considered to be induced as a result of changes within the composition of gut microbiota. The evidence gathered so far clearly advocates the involvement of gut microbes in causing obesity, a state of chronic and low-grade inflammation. Hence, understanding the microbiota of the gut is significant in relation to inflammation, as it is a key contributor for diabetes which has a direct relation to the AD pathogenesis. Comparative analysis of gut microbiota may enable further novel insight into the complex biology of AD, which is very important in order to take preventive measure such as early diagnosis, identification of new therapeutic targets and development of novel drugs.
Export Options
About this article
Cite this article as:
Alam Z. Mohammad, Alam Qamre, Kamal A. Mohammad, Abuzenadah M. Adel and Haque Absarul, A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimer’s Disease Pathogenicity: An Update, CNS & Neurological Disorders - Drug Targets 2014; 13 (3) . https://dx.doi.org/10.2174/18715273113126660151
DOI https://dx.doi.org/10.2174/18715273113126660151 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Dialogue Between Endothelial Cells and Monocytes/Macrophages in Vascular Syndromes
Current Pharmaceutical Design Heat Shock Proteins - Two Sides of a Coin
Current Cardiology Reviews Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension
Cardiovascular & Hematological Agents in Medicinal Chemistry Nucleoside Transporter Proteins
Current Vascular Pharmacology Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Oxidative Stress, Preeclampsia and Cardiovascular Disease
Current Hypertension Reviews Arterial Thickness and Immunometabolism: The Mediating role of Chronic Exercise
Current Cardiology Reviews Prostacyclin Synthase Gene: Implication and Prevention of Cardiovascular Disease
Vascular Disease Prevention (Discontinued) Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The role of the COMPASS Strategy
Current Cardiology Reviews Mast Cell Chymase and Tryptase as Targets for Cardiovascular and Metabolic Diseases
Current Pharmaceutical Design Adverse Effects of Statins - Myths and Reality
Current Pharmaceutical Design Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis
Current Pharmaceutical Biotechnology The Utility of Metformin Therapy in Reproductive-Aged Women with Polycystic Ovary Syndrome (PCOS)
Current Pharmaceutical Biotechnology Thiazolidinediones and Cardiovascular Risk — A Question of Balance
Current Cardiology Reviews A Possible Target of Antioxidative Therapy for Diabetic Vascular Complications-Vascular NAD(P)H Oxidase
Current Medicinal Chemistry Pleiotropic Effects of Nifedipine on Atherosclerosis
Current Pharmaceutical Design Preeclampsia as a Multifactorial Pregnancy Disorder: Clinical Symptoms,Diagnostic Tools and Research Strategies
Current Women`s Health Reviews Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review
Reviews on Recent Clinical Trials Type 2 Diabetes and Obesity in Children and Adolescents: Experience from Studies in Taiwanese Population
Current Diabetes Reviews Restenosis Treatments Using Nanoparticle-based Drug Delivery Systems
Current Pharmaceutical Design